309 related articles for article (PubMed ID: 17497445)
1. Effect of peritoneal dialysis solution type on serum lipid levels in end-stage renal disease.
Kanbay M; Bavbek N; Delibasi T; Koca C; Kaya A; Altay M; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2007; 29(3):309-13. PubMed ID: 17497445
[TBL] [Abstract][Full Text] [Related]
2. Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients.
Canbakan M; Sahin GM
Ren Fail; 2007; 29(3):289-93. PubMed ID: 17497442
[TBL] [Abstract][Full Text] [Related]
3. The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients.
Gürsu EM; Ozdemir A; Yalinbas B; Gürsu RU; Canbakan M; Güven B; Atasoyu EM; Keskin AT; Elçi A; Baru Y
Clin Nephrol; 2006 Oct; 66(4):263-8. PubMed ID: 17063993
[TBL] [Abstract][Full Text] [Related]
4. Glucose concentration in the dialysate does not contribute to lipid profiles in patients undergoing CAPD.
Li Z; Fengxian H
Ren Fail; 2011; 33(2):124-30. PubMed ID: 21332332
[TBL] [Abstract][Full Text] [Related]
5. [Clinical experience with icodextrin. Multicenter study].
Guerrero A; Montes R; Martín-Herrera C; Ruiz A; Remón C; Fernández-Ruiz EJ; Pérez-Bañasco V; Benítez M; Martínez-Benavides E; Martínez-González JM; Torán D; Tejuca F; Páez C; del Pino MD
Nefrologia; 2001; 21(6):574-80. PubMed ID: 11881427
[TBL] [Abstract][Full Text] [Related]
6. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis.
Babazono T; Nakamoto H; Kasai K; Kuriyama S; Sugimoto T; Nakayama M; Hamada C; Furuya R; Hasegawa H; Kasahara M; Moriishi M; Tomo T; Miyazaki M; Sato M; Yorioka N; Kawaguchi Y;
Am J Nephrol; 2007; 27(4):409-15. PubMed ID: 17622748
[TBL] [Abstract][Full Text] [Related]
7. [Lipoprotein (a) in children with end stage renal failure on maintenance hemodialysis and continuous ambulatory peritoneal dialysis].
Zwolińska D; Szprynger K
Przegl Lek; 1997; 54(5):320-3. PubMed ID: 9380806
[TBL] [Abstract][Full Text] [Related]
8. [Effect of a dialysis solution with icodextrin on ultrafiltration and selected metabolic parameters in patients treated with peritoneal dialysis].
Opatrná S; Racek J; Stehlík P; Senft V; Sefrna F; Topolcan O; Opatrný K
Cas Lek Cesk; 2002 May; 141(9):281-5. PubMed ID: 12061197
[TBL] [Abstract][Full Text] [Related]
9. Residual renal function affects lipid profile in patients undergoing continuous ambulatory peritoneal dialysis.
Kagan A; Elimalech E; Lemer Z; Fink A; Bar-Khayim Y
Perit Dial Int; 1997; 17(3):243-9. PubMed ID: 9237284
[TBL] [Abstract][Full Text] [Related]
10. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis.
Misra M; Reaveley DA; Ashworth J; Muller B; Seed M; Brown EA
Perit Dial Int; 1997; 17(3):279-86. PubMed ID: 9237290
[TBL] [Abstract][Full Text] [Related]
11. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH
Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871
[TBL] [Abstract][Full Text] [Related]
12. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.
Siamopoulos KC; Elisaf MS; Bairaktari HT; Pappas MB; Sferopoulos GD; Nikolakakis NG
Perit Dial Int; 1995; 15(8):342-7. PubMed ID: 8785232
[TBL] [Abstract][Full Text] [Related]
13. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
14. Polyglucose dialysis solution induces changes in blood chemistry.
Grzegorzewska AE; Antczak-Jedrzejczak D; Leander M; Mariak I
Adv Perit Dial; 2001; 17():101-8. PubMed ID: 11510254
[TBL] [Abstract][Full Text] [Related]
15. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
16. The uremic dyslipidemia: a cross-sectional and longitudinal study.
Avram MM; Goldwasser P; Burrell DE; Antignani A; Fein PA; Mittman N
Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199
[TBL] [Abstract][Full Text] [Related]
17. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
18. Effects of icodextrin on insulin resistance and adipocytokine profiles in patients on peritoneal dialysis.
Takeguchi F; Nakayama M; Nakao T
Ther Apher Dial; 2008 Jun; 12(3):243-9. PubMed ID: 18503703
[TBL] [Abstract][Full Text] [Related]
19. [Dyslipidemia in patients being treated with peritoneal dialysis].
Zharfbin A
Vnitr Lek; 2006 Nov; 52(11):1051-7. PubMed ID: 17165524
[TBL] [Abstract][Full Text] [Related]
20. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K
Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
